Latest news with #Rule170
Hans India
3 days ago
- Health
- Hans India
Supreme Court Dismisses IMA Petition Against Patanjali Misleading Ads
On August 11, 2025, the Supreme Court has rejected a petition filed by the Indian Medical Association (IMA). The IMA had claimed that Patanjali Ayurved's advertisements were misleading and harmed modern medicine. Rule 170 and AYUSH Advertising: On July 1, 2024, the AYUSH Ministry removed Rule 170, which required state approval before advertising Ayurvedic, Siddha, and Unani medicines. In August 2024, the Supreme Court temporarily restored the rule. Supreme Court Decision: Justice K.V. Viswanathan said that once the Centre removes a rule, states cannot enforce it. Justice B.V. Nagarathna suggested closing the case since the main reliefs sought by the IMA were already addressed. The court emphasized that a rule removed by the Centre cannot be reinstated by the court. Earlier Actions: The court examined Patanjali's misleading ads and regulatory inaction. Contempt proceedings against Patanjali were closed after repeated apologies. The court warned that banning ads or granting approvals for AYUSH medicines could encourage unfair trade practices.
India Today
6 days ago
- Business
- India Today
Advertising a natural practice: Top court closes Patanjali misleading ads case
The Supreme Court closed the Indian Medical Association's (IMA) petition against Patanjali Ayurveda over misleading claims in advertisements for traditional medicine, noting that advertising is a natural practice if manufacturing is permitted. In doing so, the top court set aside its earlier order that had imposed stricter checks and approval requirements."Once you permit manufacture, then advertisement of that product will be a natural business practice," said Justice BV Nagarathna while closing the General Tushar Mehta, representing the Union government, argued that an existing legal framework already prohibits false medical claims, rendering Rule 170 unnecessary. "There is already a statutory mechanism in us not doubt the intelligence of the common man," he said. Rule 170 had required pre-approval for traditional medicine advertisements. During the proceedings, Advocate Pranav Sachdeva, representing an intervenor, urged maintaining the status quo of the Supreme Court's earlier stay against the Ministry of AYUSH's notification omitting Rule 170. Sachdeva warned about the dangers of misleading ads, noting, "There are large number of people who are Ayurveda you can come up and say this is the cure of this disease, people will be lured."Senior Advocate Shadan Farasat, serving as Amicus Curiae, noted that since the stay in August 2024 "a lot has happened since the 27th August, 2024 order (imposing the stay)," reported Bar and Bench. "The States have been implementing the rule," he further said. Despite this, the notification deleting Rule 170 indicated a shift towards aligning traditional medicines with allopathy division's decision to close contempt proceedings against Patanjali's promoters, Baba Ramdev and Acharya Balkrishna, following their repeated apologies, allowed the company to continue operations without further legal Rule 170 was aimed at curbing exaggerated claims, its removal suggests a leaning towards less restrictive advertising practices. This change has sparked debates around the balance between consumer protection and business its final order, the top court noted that the relief sought had been achieved, and the case does not require further consideration. "It is not in dispute that the relief sought for has been achieved in as much as by various the writ petition stands disposed," the order Court emphasised the importance of maintaining a balance between consumer protection and business practices, highlighting the need for vigilance in advertising standards.- EndsTune InMust Watch
Time of India
18-05-2025
- Business
- Time of India
In a first, state regulatory authority warns Ayurvedic drug making firm
1 2 3 4 Kozhikode: In a first-of-its-kind move in the country, regulatory authorities in the state have acted against a prominent Ayurvedic drug manufacturer for violating Rule 170 of the Drugs and Cosmetics Rules, 1945, which is meant to prevent misleading advertisements. Acting on a complaint filed by ophthalmologist and RTI activist Dr K V Babu on Feb 11, the Kerala deputy drugs controller (Ayurveda) carried out an investigation and subsequently issued a stern warning to Pankajakasthuri Herbals India Pvt Ltd for alleged violation of Rule 170 which mandates that manufacturers obtain prior approval from state licensing authorities before advertising their products. The drugs controller stated that any further violation could result in stringent measures against the firm, including withdrawal of the medicine's production licence. The investigation revealed that the company had not obtained approval for the advertisement issued for Orthoherb tablet published in a Malayalam daily on Jan 9. Pankajakasthuri Herbals had in its explanation to the drugs controller said that it had withdrawn the said advertisements and assured that it would issue advertisements in future only after obtaining prior approval. Rule 170 of the Drugs and Cosmetics Rules, 1945, is designed to prevent misleading advertisements for Ayurvedic, Siddha and Unani (AYUSH) drugs. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Cost Of Amusement Park Equipment From Mexico Might Surprise You - See Tips Amusement Park Equipment | search ads Click Here Undo Specifically, it requires manufacturers to obtain prior approval from state licensing authorities before advertising their products. Dr Babu said the action taken by the deputy drugs controller (Ayurveda) was significant as it was for the first time in the country that action was taken on a complaint regarding Rule 170 after the rule was reinstated by the Supreme Court on Aug 27, 2024. Though Rule 170 was gazetted by the govt on Dec 24, 2018, it was stayed by the Delhi and Bombay high courts in 2019 and later omitted by the central govt.
Business Standard
29-04-2025
- Business
- Business Standard
First Neutral Forum for Bridging the gap between AYUSH industry and Regulators launched
PNN New Delhi [India], April 29: In recent times, the AYUSH sector has been facing challenges with regard to various tall claims on product advertisements, leading to unwanted disrepute. The Supreme Court and Ministry of AYUSH have come out heavily and the imposition of various regulations like Rule 170 and DMRA (Drug and Magic Remedies Act) have been recent talking points. With a market size of approximately USD 23 billion, about 9000 plus ASU drug manufacturers and over a Lac registered marketing companies, the AYUSH sector has seen tremendous growth, especially in the last 10-12 years. Many start-ups have also created a new online space for AYUSH products and are seeing exponential growth. This growth is predicted to continue at a rate of over 15% and achieve big milestones in the coming years. However, poor compliance with regulations, along with maintaining quality standards, has always been a challenge to the industry. Reasons for such challenges have been identified as poor awareness and a lack of professional guidance. It is also seen that business (marketing) prevails over science (Research and Development) often impacting sustainable growth. To bridge the gap between industry and regulators, a neutral platform The Nature Laws-TNL was launched on the 26th of April 2025 at India Habitat Center, New Delhi with participation from key leaders across AYSUH, Pharma, Research and Regulatory bodies, with gracious presence of Dr. Kousthubha Upadhyaya (Advisor, Ministry of AYUSH, Govt. of India) as the Guest of Honour and Dr. Rabinarayan Acharya (Director General, CCRAS) besides other dignitaries. Top Ayurveda company heads from Dabur, Himalaya, Emami, Dootpapeshwar, Multani Pharma, Marico, K Patel along with start-ups like Kapiva, Sandook sutras, actively participated in the Brainstorming session on regulations in the AYUSH sector and provided their valuable inputs and suggestions. An initiative of Dr. C K Katiyaar along with industry professionals, including Dr. Sanjay Tamoli, Dr. Arun Gupta and Dr. Sanjay Nipanikar, "The Nature Laws" is India's first neutral platform dedicated to bringing the AYUSH industry and regulators together for transparent discussions and progressive regulations. Maitri Trivedi, the Head of Operations at "The Nature Laws", informed that TNL shall provide regulatory services, foster interaction between stakeholders, provide updated training and help navigate through the regulations to enhance compliance. With a broader objective of improving the level of compliance for better growth, visibility and international impact, "TNL" will work towards providing "Success Through Compliance" by supporting the industry with awareness programs on GMP, GCP, GAP, GLP, and other regulations on a regular basis. Speaking at the event, Dr. C K Katiyaar emphasised that "TNL" is neither a certifying body nor a legal agency for the representation of companies but a service provider to facilitate compliance for achieving global standards for AYUSH products and services.
